Castle Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL) said its executive management will present a company overview at the Stephens 27th Annual Investment Conference on Nov 19, 2025 at 10:00 a.m. ET. A live audio webcast will be available at the company’s investor website and a replay will be posted after the broadcast. Castle also will be available for one-on-one investor meetings at the Jefferies Global Healthcare Conference on Nov 18–20, 2025, with meetings requestable through Jefferies Financial Group.

News Market Reaction

+0.79%

1 alert

+0.79% News Effect

On the day this news was published, CSTL gained 0.79%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

FRIENDSWOOD, Texas, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens 27^th Annual Investment Conference on Wednesday, Nov. 19, 2025, at 10:00 a.m. Eastern time.

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.

Castle will also be available for one-on-one investor meetings during the Jefferies Global Healthcare Conference, being held Nov. 18-20, 2025. Meetings may be requested exclusively through Jefferies Financial Group.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide treatment decisions for patients with moderate-to-severe atopic dermatitis. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram. 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:
Allison Marshall
amarshall@castlebiosciences.com

Source: Castle Biosciences Inc.

FAQ

When will Castle Biosciences (CSTL) present at the Stephens 27th Annual Investment Conference?

Castle will present on Nov 19, 2025 at 10:00 a.m. ET.

How can investors access Castle Biosciences (CSTL) presentation webcast on Nov 19, 2025?

A live audio webcast will be available via the company investor site at ir.castlebiosciences.com/events-presentations/ and a replay will follow the live broadcast.

Will Castle Biosciences (CSTL) hold meetings at the Jefferies Global Healthcare Conference Nov 18–20, 2025?

Yes. Castle will be available for one-on-one investor meetings during Nov 18–20, 2025; meetings must be requested through Jefferies Financial Group.

Does the Castle Biosciences (CSTL) webcast include a replay if I miss the live presentation?

Yes. A replay of the webcast will be posted on the company’s investor website after the live broadcast.

Where can institutional investors request one-on-one meetings with Castle Biosciences (CSTL) at Jefferies?

Meetings may be requested exclusively through Jefferies Financial Group, per the conference instructions.